Benzinga Research

Get Benzinga Pro
Data & APIs
Events
Premarket
Advertise

Premium Services
Financial News
Latest
Earnings
Guidance
Dividends
M&A
Buybacks
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Small-Cap
Markets
Pre-Market
After Hours
Movers
ETFs
Options
Cryptocurrency
Commodities
Bonds
Futures
Mining
Real Estate
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Investing Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
Analyst Ratings
Analyst Color
Latest Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers

Free Benzinga Pro Trial

Calendars

Analyst Ratings Calendar

Conference Call Calendar

Dividend Calendar

Earnings Calendar

Economic Calendar

Guidance Calendar

Unusual Options Activity Calendar

Stock Split Calendar

Trade Ideas

Free Stock Reports

Trade Idea Feed

Analyst Ratings

Unusual Options Activity

Free Newsletter

Government Trades

Perfect Stock Portfolio

Easy Income Portfolio

Short Interest

Largest Increase

Largest Decrease

Calculators

Margin Calculator

Forex Profit Calculator

100x Options Profit Calculator

Screeners

Top Momentum Stocks

Top Quality Stocks

Top Value Stocks

Top Growth Stocks

Compare Best Stocks

Best Momentum Stocks

Best Quality Stocks

Best Value Stocks

Best Growth Stocks

Comments

Loading...

Genmab Stock News

GNMSFOTCPK

Logo brought to you by Benzinga Data

Trade with Public

Trade with Public

$316.90

-3.10-0.97%

At close: Dec 12, 4:00 PM EST

News

Latest Genmab Stock News | OTC:GNMSF | Benzinga

Get the latest news on Genmab stock with updates on market trends, financials, and analysis from Benzinga. Stay informed on Genmab performance

Categories: All

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

Thursday, August 06, 2020

GlaxoSmithKline Gets FDA Approval For Blood Cancer Drug
Shivdeep Dhaliwal

Tuesday, March 24, 2020

Stocks That Hit 52-Week Highs On Tuesday
Benzinga Insights

Tuesday, August 13, 2019

Stocks That Hit 52-Week Highs Of Tuesday
Lisa Levin

Monday, August 12, 2019

Stocks That Hit 52-Week Highs Of Monday
Lisa Levin

Sunday, October 25, 2015

Genmab Announces $3M Milestone Payment in DuoBody Platform Collaboration with Janssen
Benzinga

Monday, October 05, 2015

Genmab Reaches $3M Milestone Payment in DuoBody Platform Collaboration with Janssen
Benzinga

Friday, September 25, 2015

US Stock Futures Jump Ahead Of GDP Report
Benzinga
Genmab Announces CHMP Grants Accelerated Assessment for Daratumumab for Double Refractory Multiple Myeloma
Benzinga

Saturday, September 19, 2015

Genmab Announces FDA Grants Priority Review for Ofatumumab as Maintenance Therapy for Relapsed CLL
Benzinga

Friday, September 04, 2015

Genmab Announces FDA Grants Priority Review for Daratumumab for Double Refractory Multiple Myeloma
Benzinga

Friday, August 14, 2015

US Stock Futures Slip Ahead Of Economic Data
Benzinga
Genmab Enters Commercial License Agreement with Novo Nordisk for DuoBody Technology
Benzinga

Monday, April 27, 2015

Genmab Announces Phase III Study of Arzerra Met Primary Endpoint of Improved Progression-Free Survival in Patients with Relapsed CLL
Benzinga

Monday, March 16, 2015

Genmab Retains Partial Rights for HuMax-TAC-ADC; Won't Exercise Co-development Right
Benzinga

Monday, August 11, 2014

Genmab Announces Jannsen to Start New Phase III Study of Daratumumab in Front Line Multiple Myeloma
Benzinga

Connect With Us

About Benzinga

About Us
Careers
Advertise
Contact Us

Market Resources

Advanced Stock Screener Tools
Options Trading Chain Analysis
Comprehensive Earnings Calendar
Dividend Investor Calendar and Alerts
Economic Calendar and Market Events
IPO Calendar and New Listings
Market Outlook and Analysis
Wall Street Analyst Ratings and Targets

Trading Tools & Education

Benzinga Pro Trading Platform
Options Trading Strategies and News
Stock Market Trading Ideas and Analysis
Technical Analysis Charts and Indicators
Fundamental Analysis and Valuation
Day Trading Guides and Strategies
Live Investors Events
Pre market Stock Analysis and News
Cryptocurrency Market Analysis and News

Ring the Bell

A newsletter built for market enthusiasts by market enthusiasts. Top stories, top movers, and trade ideas delivered to your inbox every weekday before and after the market closes.

Terms & Conditions
Do Not Sell My Personal Data/Privacy Policy
Disclaimer
Service Status
Sitemap

© 2025 Benzinga | All Rights Reserved